Top

BMC Psychiatry

Published in:

Open Access 01-12-2021 | Schizophrenia | Research article

Alteration in the mRNA expression profile of the autophagy-related mTOR pathway in schizophrenia patients treated with olanzapine

Authors: Fengwei Cui, Shuguang Gu, Yue Gu, Jiajun Yin, Chunxia Fang, Liang Liu

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Background

The mammalian target of rapamycin protein (mTOR) signaling pathway is involved in the pathogenesis of schizophrenia and the mechanism of extrapyramidal adverse reactions to antipsychotic drugs, which might be mediated by an mTOR-dependent autophagy impairment. This study aimed to examine the expression of mTOR pathway genes in patients with schizophrenia treated with olanzapine, which is considered an mTOR inhibitor and autophagy inducer.

Methods

Thirty-two patients with acute schizophrenia who had been treated with olanzapine for four weeks (average dose 14.24 ± 4.35 mg/d) and 32 healthy volunteers were recruited. Before and after olanzapine treatment, the Positive and Negative Syndrome Scale (PANSS) was used to evaluate the symptoms of patients with schizophrenia, and the mRNA expression levels of mTOR pathway-related genes, including MTOR, RICTOR, RAPTOR, and DEPTOR, were detected in fasting venous blood samples from all subjects using real-time quantitative PCR.

Results

The MTOR and RICTOR mRNA expression levels in patients with acute schizophrenia were significantly decreased compared with those of healthy controls and further significantly decreased after four weeks of olanzapine treatment. The DEPTOR mRNA expression levels in patients with acute schizophrenia were not significantly different from those of healthy controls but were significantly increased after treatment. The expression levels of the RAPTOR mRNA were not significantly different among the three groups. The pairwise correlations of MTOR, DEPTOR, RAPTOR, and RICTOR mRNA expression levels in patients with acute schizophrenia and healthy controls were significant. After olanzapine treatment, the correlations between the expression levels of the DEPTOR and MTOR mRNAs and between the DEPTOR and RICTOR mRNAs disappeared.

Conclusions

Abnormalities in the mTOR pathway, especially DEPTOR and mTORC2, might play important roles in the autophagy mechanism underlying the pathophysiology of schizophrenia and effects of olanzapine treatment.

Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334–41. https://doi.org/10.1001/jamapsychiatry.2014.2502.CrossRefPubMedPubMedCentral

Ryskalin L, Limanaqi F, Frati A, Busceti CL, Fornai F. mTOR-related brain dysfunctions in neuropsychiatric disorders. Int J Mol Sci. 2018;19(8):2226. https://doi.org/10.3390/ijms19082226.CrossRefPubMedCentral

Takahashi T, Hara K, Inoue H, Kawa Y, Tokunaga C, Hidayat S, et al. Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro. Genes Cells. 2000;5(9):765–75. https://doi.org/10.1046/j.1365-2443.2000.00365.x.CrossRefPubMed

Bockaert J, Marin P. mTOR in brain physiology and pathologies. Physiol Rev. 2015;95(4):1157–87. https://doi.org/10.1152/physrev.00038.2014.CrossRefPubMed

Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110(2):177–89. https://doi.org/10.1016/S0092-8674(02)00833-4.CrossRefPubMed

Schuman EM, Dynes JL, Steward O. Synaptic regulation of translation of dendritic mRNAs. J Neurosci. 2006;26(27):7143–6. https://doi.org/10.1523/JNEUROSCI.1796-06.2006.CrossRefPubMedPubMedCentral

Kang H, Schuman EM. A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science. 1996;273(5280):1402–6. https://doi.org/10.1126/science.273.5280.1402.CrossRefPubMed

Huber KM, Kayser MS, Bear MF. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science. 2000;288(5469):1254–7. https://doi.org/10.1126/science.288.5469.1254.CrossRefPubMed

Cracco JB, Serrano P, Moskowitz SI, Bergold PJ, Sacktor TC. Protein synthesis-dependent LTP in isolated dendrites of CA1 pyramidal cells. Hippocampus. 2005;15(5):551–6. https://doi.org/10.1002/hipo.20078.CrossRefPubMed

10.

Calabrese F, Riva MA, Molteni R. Synaptic alterations associated with depression and schizophrenia: potential as a therapeutic target. Expert Opin Ther Targets. 2016;20(10):1195–207. https://doi.org/10.1080/14728222.2016.1188080.CrossRefPubMed

11.

Rial D, Puighermanal E, Chazalon M, Valjent E, Schiffmann SN, de Kerchove d'Exaerde A. Mammalian target of rapamycin-RhoA signaling impairments in direct striatal projection neurons induce altered behaviors and striatal physiology in mice. Biol Psychiatry. 2020;88(12):945–54. https://doi.org/10.1016/j.biopsych.2020.05.029.CrossRefPubMed

12.

Lin R, Learman LN, Na CH, Renuse S, Chen KT, Chen PY, et al. Persistently elevated mTOR complex 1-S6 kinase 1 disrupts DARPP-32-dependent D1 dopamine receptor signaling and behaviors. Biol Psychiatry. 2021;89(11):1058–72. https://doi.org/10.1016/j.biopsych.2020.10.012.CrossRefPubMed

13.

Pivonello C, Rousaki P, Negri M, Sarnataro M, Napolitano M, Marino FZ, et al. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. Endocrine. 2017;56(3):603–20. https://doi.org/10.1007/s12020-016-1079-2.CrossRefPubMed

14.

Brandon NJ, Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat Rev Neurosci. 2011;12(12):707–22. https://doi.org/10.1038/nrn3120.CrossRefPubMedPubMedCentral

15.

Rosa JM, Pazini FL, Olescowicz G, Camargo A, Moretti M, Gil-Mohapel J, et al. Prophylactic effect of physical exercise on Aβ1-40-induced depressive-like behavior: role of BDNF, mTOR signaling, cell proliferation and survival in the hippocampus. Prog Neuro-Psychopharmacol Biol Psychiatry. 2019;94:109646. https://doi.org/10.1016/j.pnpbp.2019.109646.CrossRef

16.

Gordillo-Salas M, Pilar-Cuéllar F, Auberson YP, Adell A. Signaling pathways responsible for the rapid antidepressant-like effects of a GluN2A-preferring NMDA receptor antagonist. Transl Psychiatry. 2018;8(1):84. https://doi.org/10.1038/s41398-018-0131-9.CrossRefPubMedPubMedCentral

17.

Pham TH, Gardier AM. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharmacol Ther. 2019;199:58–90. https://doi.org/10.1016/j.pharmthera.2019.02.017.CrossRefPubMed

18.

Lee GH, D'Arcangelo G. New insights into Reelin-mediated signaling pathways. Front Cell Neurosci. 2016;10:122.PubMedPubMedCentral

19.

Dadalko OI, Siuta M, Poe A, Erreger K, Matthies HJ, Niswender K, et al. mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission. J Neurosci. 2015;35(23):8843–54. https://doi.org/10.1523/JNEUROSCI.0887-15.2015.CrossRefPubMedPubMedCentral

20.

Mas S, Gassó P, Parellada E, Bernardo M, Lafuente A. Network analysis of gene expression in peripheral blood identifies mTOR and NF-κB pathways involved in antipsychotic-induced extrapyramidal symptoms. Pharm J. 2015;15(5):452–60. https://doi.org/10.1038/tpj.2014.84.CrossRef

21.

Mas S, Gassó P, Boloc D, Rodriguez N, Mármol F, Sánchez J, et al. Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms. Pharm J. 2016;16(3):293–300. https://doi.org/10.1038/tpj.2015.48.CrossRef

22.

Mas S, Gassó P, Ritter MA, Malagelada C, Bernardo M, Lafuente A. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway. Eur Neuropsychopharmacol. 2015;25(1):51–9. https://doi.org/10.1016/j.euroneuro.2014.11.011.CrossRefPubMed

23.

Gu S, Cui F, Yin J, Fang C, Liu L. Altered mRNA expression levels of autophagy- and apoptosis-related genes in the FOXO pathway in schizophrenia patients treated with olanzapine. Neurosci Lett. 2021;746:135669. https://doi.org/10.1016/j.neulet.2021.135669.CrossRefPubMed

24.

Al Ahmed HA, Nada O. E2F3 transcription factor: A promising biomarker in lung cancer. Cancer Biomark. 2017;19(1):21–6. https://doi.org/10.3233/CBM-160196.CrossRefPubMed

25.

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–93.CrossRef

26.

Hung CM, Garcia-Haro L, Sparks CA, Guertin DA. mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol. 2012;4(12):a008771. https://doi.org/10.1101/cshperspect.a008771.

27.

Moschetta M, Reale A, Marasco C, Vacca A, Carratù MR. Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations. Br J Pharmacol. 2014;171(16):3801–13. https://doi.org/10.1111/bph.12749.CrossRefPubMedPubMedCentral

28.

Cox AJ, Zhang P, Evans TJ, Scott RJ, Cripps AW, West NP. Gene expression profiles in whole blood and associations with metabolic dysregulation in obesity. Obes Res Clin Pract. 2018;12(2):204–13. https://doi.org/10.1016/j.orcp.2017.07.001.CrossRefPubMed

29.

Cuthbertson DJ, Babraj J, Leese G, Siervo M. Anabolic resistance does not explain sarcopenia in patients with type 2 diabetes mellitus, compared with healthy controls, despite reduced mTOR pathway activity. Clin Nutr. 2017;36(6):1716–9. https://doi.org/10.1016/j.clnu.2016.11.012.CrossRefPubMed

30.

Wang L, Zhou K, Fu Z, Yu D, Huang H, Zang X, et al. Brain development and Akt signaling: the crossroads of signaling pathway and neurodevelopmental diseases. J Mol Neurosci. 2017;61(3):379–84. https://doi.org/10.1007/s12031-016-0872-y.CrossRefPubMed

31.

Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature. 2002;417(6886):292–5. https://doi.org/10.1038/417292a.CrossRefPubMed

32.

Switon K, Kotulska K, Janusz-Kaminska A, Zmorzynska J, Jaworski J. Molecular neurobiology of mTOR. Neuroscience. 2017;341:112–53. https://doi.org/10.1016/j.neuroscience.2016.11.017.CrossRefPubMed

33.

Mostaid MS, Lee TT, Chana G, Sundram S, Shannon Weickert C, Pantelis C, et al. Peripheral transcription of NRG-ErbB pathway genes are upregulated in treatment-resistant schizophrenia. Front Psychiatry. 2017;8:225. https://doi.org/10.3389/fpsyt.2017.00225.CrossRefPubMedPubMedCentral

34.

Machado-Vieira R, Zanetti MV, Teixeira AL, Uno M, Valiengo LL, Soeiro-de-Souza MG, et al. Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder. Eur Neuropsychopharmacol. 2015;25(4):468–73. https://doi.org/10.1016/j.euroneuro.2015.02.002.CrossRefPubMedPubMedCentral

35.

Dong E, Guidotti A, Zhang H, Pandey SC. Prenatal stress leads to chromatin and synaptic remodeling and excessive alcohol intake comorbid with anxiety-like behaviors in adult offspring. Neuropharmacology. 2018;140:76–85. https://doi.org/10.1016/j.neuropharm.2018.07.010.CrossRefPubMedPubMedCentral

36.

Catena V, Fanciulli M. Deptor: not only a mTOR inhibitor. J Exp Clin Cancer Res. 2017;36(1):12. https://doi.org/10.1186/s13046-016-0484-y.CrossRefPubMedPubMedCentral

37.

Fabbri C, Serretti A. Genetics of long-term treatment outcome in bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;65:17–24. https://doi.org/10.1016/j.pnpbp.2015.08.008.CrossRef

38.

Davies J, Zachariades E, Rogers-Broadway KR, Karteris E. Elucidating the role of DEPTOR in Alzheimer's disease. Int J Mol Med. 2014;34(5):1195–200. https://doi.org/10.3892/ijmm.2014.1895.CrossRefPubMedPubMedCentral

39.

Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163–75. https://doi.org/10.1016/S0092-8674(02)00808-5.CrossRefPubMed

40.

Boloc D, Gortat A, Cheng-Zhang JQ, García-Cerro S, Rodríguez N, Parellada M, et al. Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics. Transl Psychiatry. 2018;8(1):276. https://doi.org/10.1038/s41398-018-0330-4.CrossRefPubMedPubMedCentral

41.

Siuta MA, Robertson SD, Kocalis H, Saunders C, Gresch PJ, Khatri V, et al. Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. PLoS Biol. 2010;8(6):e1000393. https://doi.org/10.1371/journal.pbio.1000393.CrossRefPubMedPubMedCentral

42.

Miyata S, Kurachi M, Sakurai N, Yanagawa Y, Ishizaki Y, Mikuni M, et al. Gene expression alterations in the medial prefrontal cortex and blood cells in a mouse model of depression during menopause. Heliyon. 2016;2:e00219.CrossRef

43.

Eriguchi Y, Kuwabara H, Inai A, Kawakubo Y, Nishimura F, Kakiuchi C, et al. Identification of candidate genes involved in the etiology of sporadic Tourette syndrome by exome sequencing. Am J Med Genet B Neuropsychiatr Genet. 2017;174(7):712–23. https://doi.org/10.1002/ajmg.b.32559.CrossRefPubMed

44.

Bernard M, Yang B, Migneault F, Turgeon J, Dieudé M, Olivier MA, et al. Autophagy drives fibroblast senescence through MTORC2 regulation. Autophagy. 2020;16(11):2004–16. https://doi.org/10.1080/15548627.2020.1713640.CrossRefPubMedPubMedCentral

45.

Aspernig H, Heimbucher T, Qi W, Gangurde D, Curic S, Yan Y, et al. Mitochondrial Perturbations Couple mTORC2 to Autophagy in C. elegans. Cell Rep. 2019;29:1399–409.e5.CrossRef

46.

Lampada A, Hochhauser D, Salomoni P. Autophagy and receptor tyrosine kinase signalling: A mTORC2 matter. Cell Cycle. 2017;16(20):1855–6. https://doi.org/10.1080/15384101.2017.1372548.CrossRefPubMedPubMedCentral

47.

Zhu Y, Zhao YF, Liu RS, Xiong YJ, Shen X, Wang Y, et al. Olanzapine induced autophagy through suppression of NF-κB activation in human glioma cells. CNS Neurosci Ther. 2019;25(9):911–21. https://doi.org/10.1111/cns.13127.CrossRefPubMedPubMedCentral

Title: Alteration in the mRNA expression profile of the autophagy-related mTOR pathway in schizophrenia patients treated with olanzapine
Authors: Fengwei Cui
Shuguang Gu
Yue Gu
Jiajun Yin
Chunxia Fang
Liang Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Schizophrenia
Olanzapine
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03394-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Alteration in the mRNA expression profile of the autophagy-related mTOR pathway in schizophrenia patients treated with olanzapine

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Mediation role of alexithymia, sensory processing sensitivity and emotional-mental processes between childhood trauma and adult psychopathology: a self-report study

Symptoms of anxiety disorders in Iranian adolescents with hearing loss during the COVID-19 pandemic

PTSD, depression and anxiety in Ebola virus disease survivors in Beni town, Democratic Republic of the Congo

Family function fully mediates the relationship between social support and perinatal depression in rural Southwest China

Acceptability of tDCS in treating stress-related mental health disorders: a mixed methods study among military patients and caregivers